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Abstract
Background: Fragile X syndrome (FXS), a common cause of intellectual disability and autism, results from the
expansion of a CGG-repeat tract in the 5′ untranslated region of the FMR1 gene to >200 repeats. Such expanded
alleles, known as full mutation (FM) alleles, are epigenetically silenced in differentiated cells thus resulting in the loss
of FMRP, a protein important for learning and memory. The timing of repeat expansion and FMR1 gene silencing is
controversial.
Methods: We monitored the repeat size and methylation status of FMR1 alleles with expanded CGG repeats in
patient-derived induced pluripotent stem cells (iPSCs) and embryonic stem cells (ESCs) that were grown for extended
period of time either as stem cells or differentiated into neurons. We used a PCR assay optimized for the amplification
of large CGG repeats for sizing, and a quantitative methylation-specific PCR for the analysis of FMR1 promoter
methylation. The FMR1 mRNA levels were analyzed by qRT-PCR. FMRP levels were determined by western blotting and
immunofluorescence. Chromatin immunoprecipitation was used to study the association of repressive histone marks
with the FMR1 gene in FXS ESCs.
Results: We show here that while FMR1 gene silencing can be seen in FXS embryonic stem cells (ESCs), some silenced
alleles contract and when the repeat number drops below ~400, DNA methylation erodes, even when the repeat
number remains >200. The resultant active alleles do not show the large step-wise expansions seen in stem cells from
other repeat expansion diseases. Furthermore, there may be selection against large active alleles and these alleles do
not expand further or become silenced on neuronal differentiation.
Conclusions: Our data support the hypotheses that (i) large expansions occur prezygotically or in the very early embryo,
(ii) large unmethylated alleles may be deleterious in stem cells, (iii) methylation can occur on alleles with >400 repeats
very early in embryogenesis, and (iv) expansion and contraction may occur by different mechanisms. Our data
also suggest that the threshold for stable methylation of FM alleles may be higher than previously thought. A higher
threshold might explain why some carriers of FM alleles escape methylation. It may also provide a simple explanation for
why silencing has not been observed in mouse models with >200 repeats.
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Background
Fragile X syndrome (FXS) is the most common heritable
form of intellectual disability and a common cause of
autism spectrum disorder [1]. FXS results from the ab-
sence of functional FMRP, the FMR1 gene product. Most
cases of FXS result from the epigenetic silencing of the
FMR1 gene that occurs when a CGG-repeat tract in the
5′ untranslated region (UTR) expands to >200 repeats.
Such alleles, known as full mutation (FM) alleles, arise
by expansion of premutation (PM) alleles with 55–200
repeats when these alleles are maternally transmitted.
Rare individuals are known who carry an unmethylated
FM (UFM) [2–10]. Such individuals show few, if any,
symptoms of FXS; although, they are at risk for the neu-
rodegenerative disorder, Fragile X-associated tremor/
ataxia syndrome (FXTAS), that is seen in PM carriers
[9–11]. How UFM alleles escape methylation is unknown.
The timing of expansion is controversial. Male FM
carriers do not have FM alleles in their sperm [12] and
do not transmit FM alleles to their offspring [13, 14].
One interpretation of these observations is that expan-
sion to the FM is a post-zygotic event that spares the
male germ line [12]. However, it is also possible that ex-
pansion occurs prior to the differentiation of the germ
line with selection against FM alleles in sperm. Since FM
alleles are difficult to replicate [15], selection may result
from the requirement for rapid cell division during
spermatogenesis. The fact that a number of embryonic
stem cells (ESCs) have been characterized in which ex-
pansion into the FM range is already present [16–18]
lends support to the idea that expansion occurs either
prezygotically or in the early embryo. Furthermore, the
maternal age effect on expansion risk suggests that most
expansions may be prezygotic [19]. However, the som-
atic mosaicism seen in many FXS patients raises the pos-
sibility that expansion also occurs in the early embryo.
An early embryonic origin for expansions would be con-
sistent with work in other repeat expansion diseases
where expansion has been reported in both patient-
derived induced pluripotent stem cells (iPSCs) [20–22]
and embryonic stem cells (ESCs) [23, 24]. Expansion in
these cells has been attributed to elevated levels of the
mismatch repair proteins that are known to be required
for expansion in different mouse models [25–28].
Methylated alleles are known to be more stable than
unmethylated ones [29]. Expansions in a FX PM mouse
model are only seen when the PM allele is on the active
X chromosome in females [30] and a retrospective
examination of data from women who carry the PM [31]
suggests that the same is true in humans. Thus, expan-
sions require the expansion-prone allele to be tran-
scribed or present in a region of open chromatin.
Whether expansions and contractions arise by the same
mechanism is also unclear. The fact that the AGG
interruptions sometimes found in the FMR1 gene re-
duces expansion risk but does not affect contraction risk
suggests that the mechanisms may be different [32].
When FMR1 gene silencing occurs is also the subject
of some debate. One of the first FX ESC lines to be de-
scribed, HEFX, was transcriptionally active [16]. How-
ever, differentiation into teratomas only resulted in ~5 %
methylation. Studies of other FX ESCs led to the sugges-
tion that gene silencing only occurs late in the neuronal
differentiation process [18]. However, recent work has
demonstrated that many FX ESCs already show full or
partial silencing of the FM allele [17, 33]. This raises the
possibility that silencing occurs in the very early embryo.
Whether the silencing seen on neuronal differentiation
reflects an additional opportunity for gene inactivation is
unclear. Resolving the question of the timing of expan-
sion and gene silencing is relevant both for our under-
standing of the consequences of the FX mutation for
affected individuals and for our understanding of the
mechanisms involved.
Methods
Cell lines and culture
The iPSC line SC120 (clone 14) was provided by Dr. P.
Schwartz, Children’s Hospital of Orange County Research
Institute, California, and was derived from a fragile X pre-
mutation fibroblast cell line (SC120) using the lentivirus
method [34]. The iPSC line HT14 (clone 3) was generated
from a fragile X syndrome (FXS) patient fibroblast cell
line, C10147 [35], using an integration free protocol [36].
The control hESC line, H1 (WA01, WiCell Research Insti-
tute, Madison, WI), was obtained from Dr. Barbara Mal-
lon, NIH Stem Cell Unit (Bethesda, MD) and the FXS
hESC line, WCMC37 [18], was obtained from Nikica
Zaninovic, Weill Cornell Medical College of Cornell Uni-
versity (New York, NY). All stem cells were grown feeder-
free on Matrigel™ (BD Biosciences, Franklin Lakes, NJ)
-coated plates in mTeSR™1 medium (STEMCell Tech-
nologies, Vancouver, British Columbia, Canada). Cells
were passaged using either StemPro® Accutase® (Thermo
Fisher Scientific, Waltham, MA) or EDTA [37]. For isolat-
ing individual lineages from stem cells, single colonies
were picked and expanded in mTeSR™1 medium. Cell via-
bility and proliferation in the hESCs were measured by
the AlamarBlue® cell viability assay reagent (Thermo
Fisher Scientific) as per manufacturer’s instructions.
Briefly, 7000 cells were plated in triplicate in 96-well plates
in 100-μl medium and allowed to attach overnight. The
medium was replaced with fresh 100-μl medium and 10 μl
of Alamarblue® reagent was added. This was noted as time
0. The fluorescence was read at 590 nm in a Synergy™ 2
plate reader (BioTek, Winooski, VT) at 2, 4, 8, 12, and
24 h. The reading at each time was divided by the reading
at time 0 to correct for the differences in the starting cell
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number in each well. The 37D cells were treated with
either 1 mM caffeine or 10 μM ATM kinase inhibitor
KU55933 for 24 h and then grown in drug-free medium
for the next 3 days. Cells were passaged on the third day
and treated with the drug again for 24 h for a total of three
treatments. After the last treatment, cells were grown for
3 days in drug-free medium and harvested for DNA.
Neuronal differentiation
The SC120 cells were differentiated into post-mitotic
neurons using the previously described dual SMAD in-
hibition method [38] with some modifications. Briefly,
the iPSCs were dissociated into single cells using Stem-
Pro®Accutase® and re-plated into ultra low-attachment
dishes (Corning, Corning, NY) in KnockOut™ serum re-
placement (Thermo Fisher Scientific) based medium
with 20 ng/ml bFGF (R&D Biosystems, Minneapolis,
MN), 20 μM ROCK inhibitor (Stemgent, San Diego,
CA), 10 μM SB431542 (Stemgent), and 0.2 μM
LDN193189 (Stemgent). On the third day, the embryoid
bodies were transitioned to neural induction medium
(NIM) [DMEM/F12, 1X GlutaMAX™, 1X non-essential
amino acids (NEAA), 1X N2 supplement (all reagents
from Thermo Fisher Scientific)] supplemented with
0.2 μM LDN193189 and 10 μM SB431542. On day 6,
cells were transitioned to NIM media plus 20 ng/ml
bFGF. The neural aggregates were grown in this medium
for another 4 days with media change every other day.
After 10 days of culture in suspension, the neural aggre-
gates were dissociated and plated on dishes coated with
Geltrex® (Thermo Fisher Scientific) and cultured in NIM
media supplemented with 20 ng/ml bFGF for another
7 days. Neural rosettes were purified using the STEMdiff™
neural rosette selection reagent (STEMCell Technologies)
as per the manufacturer’s instructions. The purified neural
progenitor cells (NPCs) were plated on Geltrex-coated
dishes and cultured in neural stem cell (NSC) expansion
medium (neurobasal medium, 1X B27 supplement, 1X
NEAA, 1X GlutaMAX™ (all from Thermo Fisher Scientific)
and 20 ng/ml bFGF). For terminal differentiation into neu-
rons, NPCs were plated on polyornithine (Sigma-Aldrich,
St. Louis, MO) and laminin (Roche Applied Science, Mann-
heim, Germany) -coated dishes in NSC expansion medium
with 1X N2 supplement without bFGF. The 37D cells were
differentiated into neurons as described previously [18].
Briefly, ESCs were cultured in mTeSR™1 on Matrigel™ to
90 % confluency, followed by culture in initial differenti-
ation medium [mTeSR™1 plus 10 μM SB431542 and
250 ng/mL Noggin (R&D Biosystems)] for 5 days. Begin-
ning day 6, increasing N2 (25, 50, 75 %) was added to the
neural differentiation medium every other day. On day 12,
neural rosettes were disaggregated using StemPro®Accu-
tase® and plated onto polyornithine and laminin-coated
plates in neural differentiation medium [DMEM/F-12 with
GlutaMAX™, 1X N2, 1X B27, 20 ng/mL BDNF (R&D Bio-
systems), 20 ng/mL GDNF (Thermo Fisher Scientific),
1 mM cAMP (Sigma-Aldrich), 200 nM ascorbic acid
(Sigma-Aldrich)]. Half of the neural differentiation medium
was changed every other day.
Immunostaining
Cells were grown in 24-well plates and fixed in 4 % PFA.
Prior to immunostaining, cells were permeabilized and
blocked with 3 % Triton X-100 (Sigma-Aldrich), 10 %
normal goat serum (Thermo Fisher Scientific) in PBS for
1 h at room temperature, followed by incubation with
primary antibodies diluted in 1 % BSA (Sigma-Aldrich),
1 % normal goat serum, and 0.3 % Triton X-100 in PBS
overnight at 4 °C. The following antibodies were used:
Oct4 (Stemgent, cat # 09-0023, 1:1000), Nanog (EMD
Millipore, cat # MABD24, 1:500), Nestin (EMD Millipore,
cat # AB5922, 1:1000), MAP2 (Sigma-Aldrich, 1:500, cat #
M2320), and β-III tubulin/TuJ1 (Covance Inc., Chantilly,
VA, 1:2000). For FMRP immunostaining, the cells were
blocked and permeabilized with 5 % normal goat serum
and 0.1 % saponin (Sigma-Aldrich) for 1 h at room
temperature followed by incubation with 1:500 dilution of
FMRP antibody (Biolegend, cat # MMS-5231) in 1 % BSA
and 0.1 % saponin in PBS overnight at 4 °C. For Sox1 im-
munostaining, cells were permeabilized with 0.2 % Triton
X-100 in PBS for 15 min at room temperature, neutralized
with 100 mM glycine for 5–10 min, followed by blocking
in 3 % BSA for 45 min. The cells were then incubated with
Sox1 antibody (R&D Biosystems, cat # A11055) diluted
1:50 in 3 % BSA, 0.1 % Tween 20 (Sigma-Aldrich) in PBS
overnight at 4 °C. The cells were then incubated with ap-
propriate secondary antibodies labeled with either alexa-
488 or alexa-555 (Thermo Fisher Scientific) for 1 h at room
temperature. The nuclei were counterstained with DAPI
for 15 min at room temperature and the images acquired
using EVOS®FL Microscope (Thermo Fisher Scientific).
DNA methods
DNA was isolated from pluripotent stem cells and neu-
rons at indicated times by the salting out method [39],
and the CGG-repeat number in SC120 iPSCs and
WCMC37 hESCs and lineages derived from these cells
were analyzed by RPT-PCR and MS_RPT-PCR respect-
ively as described before [40]. Briefly, 300 ng of genomic
DNA was digested with either Fast-HindIII (Thermo
Fisher Scientific) or HindIII with HpaII (33 units/μg
DNA) (New England Biolabs, Ipswich, MA) overnight in
22.5 μl volume containing 50 mM Tris-HCl (pH 8.9),
1.5 mM MgCl2, 22 mM (NH4)2SO4, and 0.2 % Triton
X-100. Total 5 μl of digested DNA from both samples
were processed for the repeat PCR with 15-μl PCR reac-
tion mix containing a final composition of 50 mM Tris-
HCl (pH 8.9), 1.5 mM MgCl2, 22 mM (NH4)2SO4, 0.2 %
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Triton X-100, 0.5 μM of the primers Not_FraxC (5′-AG
TTCAGCGGCCGCGCTCAGCTCCGTTTCGGTTTCA
CTTCCGGT-3′) and Not_FraxR4 (5′-CAAGTCGCGGC
CGCCTTGTAGAAAGCGCCATTGGAGCCCCGCA-3′),
2.5 M betaine (Sigma-Aldrich), 2 % DMSO (Sigma-Aldrich)
and 0.27 mM each dNTP (New England Biolabs), and
0.4 units of Phusion® DNA polymerase (New England
Biolabs). The samples were then loaded onto a preheated
(>70 °C) PCR block (C1000-Touch, Bio-Rad, Hercules, CA)
and subjected to the following cycles of heating and cool-
ing: 98 °C for 3 min, 30× (98 °C for 30 s, 64 °C for 30 s, 72 °
C for 210 s) and 72 °C for 10 min. The PCR products were
resolved on TAE-1 % agarose gels and visualized with eth-
idium bromide according to standard procedures. For sam-
ples analyzed on capillary electrophoresis, Not FraxR4
primer was FAM labeled. For the HT14 iPSCs, the CGG-
repeat size was determined as previously described [41] ex-
cept that 4, 7, 2′, 4′, 5′, 7′-hexachloro-6-carboxyfluorescein
(HEX)-labeled primer frax-F (5′-AGCCCCGCACTTCCA
CCACCAGTCTCCTCCA-3′) and primer frax-C (5′-G
CTCAGCTCCGTTTCGGTTTCACTTCCGGT-3′) were
used. This primer pair produces a PCR product that con-
tains the repeat and 121 bp of DNA from the upstream
flank and 100 bp from the downstream flank for a total of
221 bp of the flanking DNA. The FMR1 promoter methyla-
tion was assessed by quantitative methylation-specific PCR
(qMS-PCR) essentially as described before [40]. Briefly,
300 ng of DNA was sonicated into <500-bp fragments
using a Bioruptor® (Diagenode, Denville, NJ) and digested
overnight with HpaII or mock digested. Quantitative PCR
using 2 μl of the mock-digested or HpaII-digested DNA
was then carried out in 5 replicates using Power SYBR®
green master mix on StepOnePlus™ Real-Time PCR ma-
chine (Thermo Fisher Scientific) in a final volume of 20 μl.
The percentage of DNA methylation was determined by
averaging the results of five technical replicates and calcu-
lating the difference in the Ct values of the digested and
mock-digested samples using the ΔΔCt method. FMR1
promoter region was amplified using primers FMR1 ex 1
(F) (5′-GAACAGCGTTGATCACGTGAC-3′) and FMR1
ex 1 (R) (5′-GTGAAACCGAAACGGAGCTGA-3′). The
efficiency of HpaII digestion was assessed by amplification
of an unmethylated region of GAPDH using primers
GAPDH exon1 (F) (5′-TCGACAGTCAGCCGCATCT-3′)
and GAPDH intron1 (R) (5′-CTAGCCTCCCGGGTTTCT
CT-3′). Additionally, DNA methylation at 22 CpG residues
in the FMR1 promoter in WCMC37 p45 cells was also ana-
lyzed by pyrosequencing of bisulfite-converted DNA by
EpigenDx, Inc. (Hopkinton, MA) using assays ADS1451-
FS1 and ADS1451-FS2.
RNA methods
Total RNA was isolated using Trizol™ (Thermo Fisher
Scientific) as per the manufacturer’s instructions. Three
hundred nanograms of total RNA was used for cDNA
synthesis using VILO™ master mix (Thermo Fisher
Scientific) in 20-μl reaction volume. FMR1 and β-glucu-
ronidase (GUS) mRNAs were quantified by real-time
PCR using TaqMan® Fast Universal PCR master mix
(Thermo Fisher Scientific) and TaqMan probe-primer
pair (FAM™ for FMR1 and VIC® for GUS, Thermo Fisher
Scientific) on StepOnePlus™ Real-Time PCR machine
(Thermo Fisher Scientific).
Western blotting
For making total cell lysates, cells were harvested in the
growth medium and pelleted at 250 × g for 6 min. The
cell pellet was washed with ice-cold PBS supplemented
with 1X protease inhibitor cocktail (Sigma-Aldrich) and
1X phosphatase inhibitor (Sigma-Aldrich). The pellet
was then resuspended in the lysis buffer (10 mM Tris Cl
pH 7.5, 1 mM EDTA pH 8.0, 1 % Triton X-100, 1X pro-
tease inhibitor cocktail, and 1X phosphatase inhibitor)
and incubated on ice for 10 min followed by sonication
to solubilize proteins and shear the DNA. The amount
of protein in the lysate was quantified using Bio-Rad
Protein Assay Dye Reagent Concentrate (Bio-Rad La-
boratories, Inc., Hercules, CA) as per manufacturer’s
protocol. Proteins were heated for 10 min at 70 °C in
LDS sample buffer (Thermo Fisher Scientific) before
running on the gel. Ten micrograms of lysates were run
on NuPAGE™ 3–8 % Tris-Acetate gels (Thermo Fisher
Scientific) and transferred to nitrocellulose membrane
using the iBlot transfer apparatus (Thermo Fisher
Scientific) as per the manufacturer’s instructions.
Membranes were blocked in 5 % membrane blocking
agent (GE Healthcare Bio-Sciences, Pittsburgh, PA) di-
luted in TBST for 1 h at room temperature. The blot
was then incubated with specific primary antibodies, di-
luted in blocking solution, overnight at 4 °C. Primary
antibodies and their dilutions were as follows: FMRP
(EMD Millipore, cat # MAB 2160) 1:2000, MSH2
(Abcam, Cambridge, MA, cat # Ab 70270) 1:10,000,
MSH3 (Santa Cruz Biotechnology, Inc., Dallas, TX, cat #
sc-271079) 1:1000, MSH6 (BD Biosciences, cat #
BD610918) 1:1000, β-actin (Abcam, cat # ab8226)
1:5000. HRP-labeled secondary antibodies were used at a
dilution of 1:5000. The detection was done using the
ECL™ Prime western blotting detection reagent (GE
Healthcare Bio-Sciences) and imaged using Fluorchem™
M imaging system (Proteinsimple, Santa Clara, CA). The
blot was then probed with antibody against β-actin, which
was used as a loading control.
Chromatin immunoprecipitation (ChIP) assay
To prepare chromatin for immunoprecipitation, cells
were fixed with 1 % formaldehyde for 10 min at room
temperature and lysed as per the kit manufacturer’s
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instructions. The chromatin was sonicated into <500-bp
fragments using a Bioruptor® (Diagenode, Denville, NJ).
ChIP assays were performed using a ChIP assay kit from
EMD Millipore as described previously [42]. Real-time
PCRs on the immunoprecipitated DNAs were carried
out in triplicate in 20-μl final volume using the Power
SYBR™ Green PCR master mix (Thermo Fisher
Scientific) and 200 nM of each primer and 2 μl of DNA.
For amplification of FMR1 exon1, the primer pair Exon1-
F (5′-CGCTAGCAGGGCTGAAGAGAA-3′) and Exon1-
R (5′-GTACCTTGTAGAAAGCGCCATTGGAG-3′) was
used. This primer pair amplifies the region +236 to +312
relative to the transcription start site. GAPDH was ampli-
fied with primers GAPDH exon1 (F) and GAPDH intron1
(R). For quantitation, the comparative threshold (Ct)
method was used. Enrichment over 5 % of input was
calculated and was normalized to GAPDH.
Results and discussion
Contractions but no expansions are seen in stem cells
and in stem cell-derived neurons
We have previously shown that relatively limited CGG
expansion is seen in human lymphoblastoid cells or
brains of premutation carriers [41]. Since extensive ex-
pansions are seen in iPSCs from patients with other re-
peat expansion diseases [43], we examined CGG
instability in two male PM iPSC lines, HT14 and SC120.
Since FXS affects males, should expansion occur in the
early embryo, expansion in male stem cells might be ob-
served. HT14 had ~105 CGG repeats at passage 9 (p9),
with a small fraction of cells having ~92 repeats, while
SC120 had ~92 CGG repeats at p28 (Fig. 1). Both lines
were positive for key pluripotency markers (Additional
file 1: Figure S1a). Notably, despite the lack of DNA
methylation (Additional file 1: Figure S1c), the level of
FMRP expression was much lower in SC120 iPSCs than
in H1 hESCs with a normal FMR1 allele (Additional file
1: Figure S1d–e). Thus, even 92 repeats significantly re-
duces FMR1 translation in stem cells, a factor that may
contribute to pathology seen in PM carriers.
Both iPSC lines were grown for extended times in cul-
ture and the CGG-repeat length monitored by PCR and
capillary electrophoresis as described in the “Methods”
section. No expansions were seen (Fig. 1) despite the fact
that such alleles are associated with ~100 % risk of ex-
pansion into the full mutation range on maternal trans-
mission [32]. In the HT14 cell line, the smaller allele
became more prominent with time while a contraction
became apparent in the SC120 cell line (Fig. 1). An in-
crease of 2 repeats was seen during the transition from
SC120 iPSCs to neuronal progenitor cell (NPC) stage
that may reflect heterogeneity in the original cell line
and the repeat remained unchanged on further differen-
tiation into neurons up to 9 weeks in culture. Plating of
HT14 cells at low density resulted in lineages with in-
creased representation of contracted alleles (Fig. 1c)
Some of these lineages shared a similar set of contracted
alleles (e.g., HT14-1 and HT14-16) suggesting that they
may have been present at low levels in the parent culture
and that the stress associated with growth at low density
may have favored the growth of cells with smaller repeat
numbers. This stress may be related to the fact that the
repeats impede DNA replication [15], an effect that
may be particularly problematic when rapid cell div-
ision is required.
The high expansion frequency seen in Friedreich
ataxia (FRDA) and myotonic dystrophy type 1 (DM1)
iPSCs has been attributed to the elevated levels of the
mismatch repair proteins important for expansion in
stem cells [20, 43]. However, the level of these proteins
in PM iPSCs was comparable to that seen in H1 ESCs
(Additional file 1: Figure S1f) that have levels of these
proteins similar to those in FRDA hiPSCs [43]. Since the
PM iPSCs may have repeat numbers too small to show
extensive expansion over the relatively short experimen-
tal time frame, we acquired an NIH-approved FX ESC
line, WCMC37, that was previously reported to carry an
unmethylated, active FM allele with ~450 CGG repeats
[18]. Analysis of alleles with this number of repeats is
difficult because amplification through the repeats is im-
paired by the secondary structures formed by the repeat
[44]. In addition, unmethylated alleles show a high de-
gree of size heterogeneity [29]. It is thus challenging to
get an accurate representation of the distribution of re-
peat sizes and methylation status in a population of cells.
We therefore analyzed these cells using a methylation-
sensitive repeat (MS_RPT)-PCR assay we developed that
accurately reflects the proportion of a wide range of al-
lele sizes and their methylation status, together with a
second more quantitative promoter methylation assay,
the qMS-PCR assay, that does not involve amplification
through the repeat [40]. The WCMC37 ESCs contained
a mixture of alleles with ~410–550 repeats (Fig. 2a).
These alleles were resistant to predigestion with the
methylation-sensitive enzyme HpaII prior to PCR
(Fig. 2a). Pyrosequencing (Fig. 2b) and the qMS-PCR
assay (Fig. 2c) showed ~ 100 % methylation of the FMR1
promoter. WCMC37 cells also showed elevated levels of
the repressive histone marks (Fig. 2d) present on si-
lenced alleles in differentiated cells [45] and FMR1
mRNA levels were ~5 % of normal. Immunostaining
with an FMRP antibody showed that very little FMRP
is produced in these cells (Additional file 1: Figure
S1d). An average of 95 % of cells were positive for
Nanog and 97 % were positive for Oct4 (Additional
file 1: Figure S1a). Thus the bulk of the WCMC37
cell culture was silenced even in the absence of differ-
entiation. It is possible that the differences in this
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study and that of Colak et al. [18] reflects differences
in the passage number of the cells used. However, the
large EcoRI-Eag1 fragment seen in southern blots in
the previous reports (Fig. S1 of [18], Fig. 3b of [46],
and Fig. 2a and Fig. S1 of [33]) would be consistent
with even early passage cultures of WCMC37 con-
taining significant numbers of cells in which the FM
allele was already silenced.
Propagation of WCMC37 cells for 22 passages showed no
clear evidence of instability (Additional file 2: Figure S2a).
However, of 6 individual sub-populations that we isolated
from this culture, all had undergone contractions (Fig. 2a).
It may be that as with the PM lines, the stresses associated
with growth at low cell density favor more rapid growth and
thus the loss of repeats that we have shown to impede DNA
replication [15, 44].
A threshold for stable methylation is seen in FX ESCs
Interestingly, contracted alleles with >400 repeats like
those in lines 37E, 37F and the largest allele in 37C
Fig. 1 CGG-repeat instability in iPSCs from PM carriers. CGG-repeat size analysis was done by RPT-PCR followed by capillary electrophoresis as de-
scribed in the “Methods” section for the hiPSCs HT14 (a) and SC120 iPSCs (b), individual lines derived from HT-14 iPSCs (c) and neuronal cells de-
rived from SC120 iPSC (d). See Additional file 1: Figure S1a for pluripotency marker staining for these cells and Additional file 1: Figure S1b for
neuronal differentiation of SC120 cells
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remained hypermethylated, while alleles with <400 re-
peats like those in 37A, 37B, 37C, and 37D became
unmethylated or partially unmethylated (Fig. 2a, c).
Further propagation of 37D, which contains a mixture of
similarly sized methylated and unmethylated alleles all
<400 repeats (Fig. 2a), resulted in the complete loss of
Fig. 2 CGG-repeat instability in FX ESCs. a CGG-repeat size and methylation analysis for the WCMC37 ESCs and the individual lineages derived
from it was done by MS_RPT-PCR followed by agarose gel electrophoresis as described in the “Methods” section. The “+” and “−“ signs indicate
the presence or absence of predigestion by the methylation-sensitive restriction enzyme, HpaII. M, 100-bp DNA size ladder and rpts, CGG repeats.
b Pyrosequencing analysis of DNA methylation in the FMR1 promoter of WCMC37 and 37A cells at passage 44 and 48, respectively. c qMS-PCR
analysis of DNA methylation in the FMR1 promoter of the samples analyzed in a. The extent of methylation was determined by the ΔΔCt method
and the individual technical replicates varied by <0.3 Ct. d The abundance of total histone H3, H3K9me2, H3K9me3, H3K27me3, and H4K20me3
in the FMR1 exon1 region is shown relative to GAPDH. Data shown are an average of two independent experiments and error bars represent
standard deviation. The 37A line at passage 59 (p59) showed the presence of mostly active FMR1 alleles with only 15 % DNA methylation, consist-
ent with the low levels of repressive histone marks on the FMR1 exon1 compared to WCMC37 cells that carry a silenced FMR1 allele. The passage
number of the cells used in panels a and c are as follows: WCMC37 p44, 37A p48, 37B p53, 37C p55, 37D p55, 37 F p55, 37E p55. See Additional
file 1: Figure S1a for pluripotency marker staining in WCMC37 cells
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all traces of the methylated allele (Fig. 3a). This methyla-
tion loss may reflect a threshold for methylation
maintenance in these cells of ~400 repeats. While it is
possible that this methylation threshold varies between
different cell lines or FM carriers, it should be noted that
the first FX ESC line isolated, HEFX had a repeat num-
ber of ~300 and was unmethylated [16]. Furthermore,
many other FX ESC lines have since been described that
contain a mixture of methylated and unmethylated
alleles with the methylated alleles having ~400 or more
repeats and the unmethylated ones having fewer than
~400 repeats [17, 33]. Additionally, many carriers of
UFM alleles also have <400 repeats [5, 8, 10, 47].
Thus, our data, in combination with data from mul-
tiple UFM carriers, raise the possibility that the thresh-
old for stable methylation is higher than generally
assumed. If so, then carriers of UFM alleles may not
have second site mutations that prevent silencing but ra-
ther do not methylate their FM allele because their re-
peat number is below the methylation threshold.
The loss of methylation in FX ESCs with <400 repeats
may reflect the more dynamic methylation in ESCs rela-
tive to differentiated cells [48, 49]. This dynamic nature
may result from exclusion of the methyltransferase re-
sponsible for maintenance methylation, DNMT1, from
the nucleus during early embryonic development [50], in
combination with elevated expression of ten-eleven
translocation (Tet) family of proteins responsible for ac-
tive DNA demethylation [51]. We speculate that while
contracted alleles are rapidly demethylated in ESCs
when their repeat number drops below ~400, alleles that
contract in differentiated cells may not lose their methy-
lation as easily, because active demethylation is reduced
and these cells rely more heavily on the clonal propagation
Fig. 3 Selective growth advantage of cells carrying methylated FMR1 alleles with large CGG repeats. a–c The repeat size, methylation status, and
FMR1 mRNA levels of the indicated cultures were monitored as described in the “Methods” section. The “+” and “−” signs indicate the presence
or absence of predigestion by the methylation-sensitive restriction enzyme, HpaII. M, 100-bp DNA size ladder and rpts, CGG repeats. a, b Data for
37D and 37A lineages that were maintained in culture for extended periods of time. The DNA methylation status is indicated by the grey line and
symbols in the right hand panel, and the mRNA level is indicated by the black line and symbols. c Growth of methylated 37A and unmethylated
37D cells. Late passage 37A cells that were completely methylated and late passage 37D cells that were unmethylated were either grown separately (i)
or in a ~1:1 mixture (ii) for ~20 passages. S refers to the cells at the start of the experiment and E to the cells at the end of the experiment. Data for the
mixed cultures are shown from two independent experiments (Rep 1 and Rep 2). Panel (iii) shows the DNA methylation for each set of cultures at the start
and end of the experiment as an average from two experiments and the error bars indicate standard deviation
Zhou et al. Molecular Autism  (2016) 7:42 Page 8 of 13
of epigenetic memory via maintenance methylation [49].
This may account for those FM carriers with methylated
alleles of 200–400 repeats. It could also account for a case
we recently described of a male with a broad range of het-
erogeneous unmethylated FM alleles and two methylated
PM alleles [40], as well as those individuals who inherit
FM alleles that subsequently lose all of their repeats by
contraction yet retain DNA methylation [52].
While unmethylated alleles were unstable showing
both small increases and decreases in repeat number, no
evidence was seen of the large step-wise increase in re-
peat number observed for stem cells from patients with
FRDA and DM1 [20–24]. This contrasts with what is
seen in FRDA stem cells where alleles with 323 repeats
gained 9.6 GAA/TTC repeats with each passage and al-
leles with 433 repeats gained 13.3 repeats [43]. The in-
stability that we observed is more reminiscent of
microsatellite instability (MSI) where repeats are as
likely to be lost as gained. Work in a mouse model sug-
gests that MSI is likely to arise via a very different mech-
anism from expansion since mismatch repair proteins
protect against MSI, while they are required for expan-
sion [53–55]. Retrospective examination of data from a
previously published paper shows a very similar MSI-like
pattern of instability for WCMC37 ESCs and a second
FX ESC line, SI-214 [33]. In this report, the cells were
grown in conditions similar to those used in the studies
of FRDA and DM1 iPSCs where expansions were seen
[33]. Thus, the failure to see expansion may not be re-
lated to the particular growth conditions used. Further-
more, as seen in Additional file 2: Figure S2b, we saw no
evidence of expansion when we treated the WCMC37
cells with caffeine, an inhibitor of the ATR DNA damage
response pathway, or KU55933, an inhibitor of the ATM
DNA damage response pathway. These two pathways
have been implicated in the expansion process in a
mouse model [56, 57]. Thus, our data suggest either that
expansion in FXS ESCs occurs at a much lower frequency
than it does in diseases like FRDA or that it occurs pri-
marily in the oocyte and/or in the very early embryo.
In the case of the 37D lineage, the methylated and
unmethylated alleles were similar in size. This would be
consistent with the unmethylated alleles having arisen
from the methylated allele after contraction had oc-
curred. Thus, it may be that unlike expansions that re-
quire transcriptionally competent chromatin [2, 30, 58],
contractions can occur from methylated alleles.
Large active alleles may be at a selective disadvantage
One WCMC37-derived line, 37A, did initially contain a
mixture of larger methylated FM alleles and smaller
unmethylated ones (Figs. 2a and 3b). However, the
largest methylated FM allele was the same size as the
largest allele seen in the parental culture. Thus, it is
likely that this allele represents an allele present in the
original population rather than an expansion product.
The culture initially showed ~25 % methylation (Fig. 3b).
However, on extended propagation the smaller unmethy-
lated allele disappeared completely, methylation rose to
100 % and no FMR1 mRNA was produced (Fig. 3b).
To test whether selection could explain how the larger,
methylated allele came to dominate the culture, we
mixed equal numbers of cells from a late passage 37A
culture containing completely methylated alleles, with
cells from a late passage of a different WCMC-derived
line, 37D that was completely unmethylated. However,
after 49 days in co-culture, there was no trace of the
smaller, unmethylated alleles in the MS_RPT-PCR assay
(Fig. 3c (ii)) or evidence of unmethylated alleles in the
qMS-PCR (Fig. 3c (iii)). This is not because the FX allele
in 37D cells had also expanded since that same line grown
in isolation did not produce such an allele (Fig. 3a, c (i)).
Thus, our results suggest that the larger, inactive allele has
a growth advantage over the smaller, unmethylated allele
as seen with 37A (Fig. 3b).
Transcripts produced from PM alleles are thought to
be responsible for FXTAS pathology, either because they
sequester essential proteins [59] or because the tran-
scripts support repeat-associated non-AUG (RAN) trans-
lation that generates a toxic protein [60]. Symptoms of
FXTAS are seen in carriers of UFM alleles [9–11] demon-
strating that active FM alleles are similarly deleterious. It
is possible that the deleterious effects of active FM alleles
are manifest even in ESCs and thus explain the selective
advantage of cells with silenced alleles. However, no obvi-
ous differences were seen in the viability or growth rate of
early passages of 37A containing a mixture of active and
silenced alleles and late passage cells containing only si-
lenced alleles in the Alarmablue assay. Nor was there any
significant difference in the viability of late passage 37A
cells and 37D. However, given the relatively slow rate at
which selection occurred, this may not be surprising and
more work is need to determine whether this selection
reflects the deleterious consequences of expression of
unmethylated alleles or genetic changes in the 37A lineage
that confers some sort of methylation-independent growth
advantage.
Active FM alleles with <400 repeats do not become
silenced on neuronal differentiation
While differentiation into neurons was associated with
high levels of cell death in two independent trials, no
evidence of FMR1 gene silencing was seen when suc-
cessful neuronal differentiation was observed (Additional
file 3: Figure S3), as evidenced by the fact that the DNA
was completely sensitive to HpaII predigestion in the
MS_RPT-PCR assay and the qMS-PCR assay showed no
change in the percentage of DNA methylation (Fig. 4).
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Thus, in a cell line derived from progenitor cells with
the demonstrated ability to complete the silencing
process, active FM alleles with <400 repeats do not be-
come silenced on neuronal differentiation. In previous
experiments in which the HEFX cell line, which has
~300 repeats, was differentiated into teratomas, a dra-
matic decrease in transcription was seen. However, this
decrease was associated with just 5 % methylation [16].
Subsequent studies of the differentiation of other FX
ESCs into neurons also showed a significant decrease in
transcription [61] and/or an increase in heterochromatic
marks characteristic of silenced genes [18]. However,
these studies used ESC lines with alleles that were at
least partially silenced and from the data provided it is
not possible to distinguish between de novo gene silen-
cing and selection for silenced alleles that were already
in the original ESC population.
Conclusions
In summary, we have shown that contractions occur in
PM iPSCs and in FM ESCs but not the large, progres-
sive, and step-wise increases in repeat number seen in
ESCs and iPSCs associated with other repeat expansion
diseases [20, 43]. Thus even though stem cells express
high levels of mismatch repair proteins that have been
suggested to account for expansions seen in stem cells
from other repeat expansion disorders [43], this is not
sufficient to trigger significant levels of expansion in FX
stem cells. This would be consistent with genetic data
from humans [19] and mouse models [27] that suggest
that the expansions that give rise to FXS occur in the
oocyte. Since oocytes do not divide, this would support a
model in which expansions result from aberrant DNA
repair or recombination rather than a problem with
DNA replication. This idea would be compatible with
work in mice that suggests that expansion occurs as a
result of the interaction of mismatch repair proteins with
base excision repair proteins [27, 53]. Some of the con-
tractions we observe likely arise from alleles that are
methylated. Since expansions do not occur from methyl-
ated alleles [29, 30], this supports the hypothesis that ex-
pansions and contractions occur by different mechanisms
[32].
We have also shown that there is a threshold for
methylation stability in the WCMC37 ESC line of ~400
repeats and that FM alleles with <400 repeats that are
unmethylated in ESCs do not become re-methylated
either on propagation as ESCs or on differentiation into
neurons. Since many UFM alleles have <400 repeats
[5, 8, 10, 47], such a methylation threshold may ex-
plain why they escape methylation. R-loops formed by the
repeat tract have recently been suggested to play a role in
FMR1 gene silencing [18, 62]. It is possible that 400 re-
peats represents the minimum number of repeats required
to produce an R-loop that is large enough or stable
enough to trigger silencing. Mice with FM alleles with
<400 repeats also do not show silencing [63, 64]. If mice
have a similar methylation threshold as humans, a mouse
model with >400 repeats may be useful for recapitulating
early developmental events in FXS.
Dynamic methylation in ESCs and the clonal propaga-
tion of methylation in differentiated cells might result in
contractions having different consequences depending
on whether they occur early or late in embryonic devel-
opment. Contractions to <400 repeats in the very early
embryo may be more likely to result in unmethylated al-
leles that could contribute to the risk of FXTAS symp-
toms. In contrast, contractions occurring later may
result in alleles that retain their DNA methylation and
thus contribute to the symptoms of FXS.
Our data also raises the possibility that selection
favors the accumulation of large, silenced alleles. If
true, this would make it difficult to distinguish
between differentiation-induced silencing [18] and
Fig. 4 Unmethylated FM alleles do not become silenced on differentiation into neurons. The repeat size, methylation status, and FMR1 mRNA
levels of the indicated cultures were monitored as described in the “Methods” section. The “+” and “−” signs indicate the presence or absence of
predigestion by the methylation-sensitive restriction enzyme, HpaII. M, 100-bp DNA size ladder and rpts, CGG repeats. A late passage culture of
37D ESCs containing little, if any methylated alleles, was differentiated into neurons as described in the “Methods” section. Methylation levels were
measured by qMS-PCR on the indicated number of days after the initiation of neuronal differentiation. See Additional file 3: Figure S3 for representative
images during neuronal differentiation of 37D cells
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selection for silenced alleles in an initially heteroge-
neous cell population. It would also have potential
implications for both PM and UFM carriers. Both PM
and UFM carriers are at risk of FXTAS [9–11], and
our data suggest that the deleterious effects of such
alleles may begin to be apparent very early in life.
Additional files
Additional file 1: Figure S1. Analysis of premutation iPSCs and full
mutation ESCs. a Immunostaining for pluripotency markers in SC120 and
HT14 iPSCs and WCMC37 ESCs. Cells were grown in 24-well plates, fixed
and stained for the indicated pluripotency markers (red) as described in
the supplemental experimental procedure. Nuclei were stained with DAPI
(blue). Scale bar: 200 μm. b SC120 iPSCs were differentiated into neurons
and stained for neuronal markers. SC120 neural progenitor cells (NPC)
were stained at passage 2 with Nestin (green) and Sox1 (red). Scale bar:
200 μm. SC120 neurons were stained at 4 weeks of differentiation with
Map2 (red) and TuJ1 (red). Nuclei were stained with DAPI (blue). Scale
bar: 100 μm. c DNA methylation at the FMR1 promoter was analyzed by
qMS-PCR in SC120 iPSCs, NPCs, and neurons at indicated weeks (wk) of
differentiation. d Immunostaining for FMRP (red) was done in indicated
cell lines. The percentage of FMRP-positive cells is indicated under each
panel. In SC120 iPSCs, all the cells were positive for FMRP expression but
the intensity was much reduced compared to the control H1 cells. Scale
bar: 100 μm. e Western blot for FMRP levels in indicated cell lines. β-Actin
is used as loading control. f Western blot analysis for MSH2, MSH3, and
MSH6 proteins in stem cells and fibroblasts was done as described in the
supplemental experimental procedures. β-Actin is used as loading control.
(TIFF 11721 kb)
Additional file 2: Figure S2. CGG-repeat size in FX ESCs. a WCMC37
cells were grown in culture for 22 passages and CGG-repeat size was
analyzed by RPT-PCR. b 37D p70 cells were treated with either 1 mM caffeine
or 10 μM of the ATM kinase inhibitor KU55933 for 24 h and then grown in
drug-free medium for the next 3 days. Cells were passaged on the third day
and treated with the drug again for 24 h for a total of three treatments. After
the last treatment, cells were grown for 3 days in drug-free medium and
harvested for DNA. The CGG-repeat size was analyzed by RPT-PCR.
(TIFF 11721 kb)
Additional file 3: Figure S3. Neuronal differentiation of 37D ESCs. Top
panel shows the immunostaining for pluripotency markers (red) in 37D
cells that were used for the neuronal differentiation experiments shown
in Fig. 2d. The differentiating cells (bottom panels) were stained for
neuronal markers at indicated days. Nestin (red), Map2 (red), TuJ1 (green).
Nuclei were stained with DAPI (blue). Scale bar: 200 μm. (TIFF 11721 kb)
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